Pharmaceutical Sodium Nitrite Purification and Carbon Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing sodium nitrite raw material does not meet the new, stringent FDA quality standards for pharmaceutical grade Good Manufacturing Practices, and there is a lack of effective analytical methods to determine total non-volatile organic carbon and detect anti-caking agents in sodium nitrite samples, hindering the development of FDA-approved clinical therapies.
Innovation Solution
Purified sodium nitrite is produced with specifications meeting FDA standards, including low sodium carbonate, anti-caking agent content, and controlled water and non-volatile organic carbon levels, along with an analytical method using supercritical water oxidation to determine total non-volatile organic carbon.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional analytical methods are used to determine total non-volatile organic carbon, then the analysis can be performed using standard procedures, but sodium nitrite explodes at temperatures above 538°C and converts to nitric oxide in acid, causing false signals and catalyst fouling
Solution Approach 1:
The patent changes the analytical parameters by using a different temperature range and chemical environment that avoids sodium nitrite decomposition. Instead of high-temperature combustion (above 538°C) and acid treatment, the method uses conditions where sodium nitrite remains stable, thereby eliminating explosion hazards and false nitric oxide signals while still enabling accurate total non-volatile organic carbon measurement.
Solution Approach 2:
The patent introduces an intermediary approach by using a modified analytical method that includes specific sample preparation steps and detection conditions. The method acts as an intermediary between the need for accurate carbon measurement and the requirement to avoid sodium nitrite decomposition, using controlled chemical environment and temperature management to prevent harmful reactions.
2Productivity
If existing sodium nitrite raw material is used, then production can continue with current suppliers, but the material does not meet new FDA quality specifications for pharmaceutical grade Good Manufacturing Practices
Solution Approach 1:
The patent applies preliminary action by establishing purified sodium nitrite production methods and quality control procedures before FDA approval is sought. The purification process and analytical methods are developed and validated in advance, ensuring that when the new drug application is submitted, the raw material already meets all pharmaceutical grade specifications, avoiding delays in regulatory approval.
Solution Approach 2:
The patent changes the quality parameters of sodium nitrite raw material by implementing purification processes that reduce impurities to levels meeting FDA specifications. This includes controlling anti-caking agent content, water content, and other quality attributes, transforming the material from food grade to pharmaceutical grade while maintaining production capability.
3Ease of operation
If anti-caking agents are added to sodium nitrite, then handling and flow properties improve, but the content must be detected and limited to meet new FDA quality standards
Solution Approach 1:
The patent implements feedback by developing analytical methods to detect and quantify anti-caking agent content in sodium nitrite. This feedback mechanism allows manufacturers to monitor and control anti-caking agent levels, adjusting formulation and processing to ensure compliance with FDA limits while maintaining adequate flow properties for handling.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The purified sodium nitrite meets FDA quality standards, enabling the development of FDA-approved clinical therapies and providing effective treatments for conditions such as cyanide and hydrogen sulfide poisoning.
Implementation Method 1
an analytical method using supercritical water oxidation to determine total non-volatile organic carbon
Data Source
AI summary
Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.